<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04576819</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201903081-N</org_study_id>
    <secondary_id>1R01GM133815-01A1</secondary_id>
    <nct_id>NCT04576819</nct_id>
  </id_info>
  <brief_title>Role and Mechanisms of Lipid and Lipoprotein Dysregulation in Sepsis</brief_title>
  <official_title>Role and Mechanisms of Lipid and Lipoprotein Dysregulation in Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lipids and lipoproteins (cholesterol and lipid metabolites) are present in sepsis and are&#xD;
      highly biologically active regulators of inflammation, but currently the changes in lipid and&#xD;
      lipoprotein homeostasis during sepsis are not well understood. This project will investigate&#xD;
      the changes in lipid and lipoprotein function, oxidation, metabolites, and changes in gene&#xD;
      expression to further our understanding of dysregulated lipid and lipoprotein metabolism in&#xD;
      sepsis. We will analyze a bank of samples and make associations with important clinical&#xD;
      outcomes (early death, chronic critical illness and sepsis recidivism) as supported by our&#xD;
      published work, and will confirm our findings in a small prospective cohort of sepsis&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will use biobanked samples from a diverse cohort of 165 sepsis patients (UF&#xD;
      Jacksonville and UF Gainesville) and will confirm findings in a small prospective cohort of&#xD;
      50 patients. The following will be tested in patient samples:&#xD;
&#xD;
      Aim 1: Test and compare HDL and LDL function (oxidation/transport) in sepsis patients by&#xD;
      clinical outcomes of rapid recovery, early death, CCI, and sepsis recidivism.&#xD;
&#xD;
      Aim 2: Determine the changes in lipid homeostasis and patterns of inflammation that occur in&#xD;
      sepsis patients by outcome.&#xD;
&#xD;
      Aim 3: Characterize cholesterol &amp; lipoprotein-specific metabolic gene expression in whole&#xD;
      blood leukocytes and peripheral blood mononuclear cells from sepsis patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Chronic Critical Illness or Early Death</measure>
    <time_frame>14 days from sepsis onset</time_frame>
    <description>CCI defined as admission to ICU &gt; 14 days total with organ dysfunction, Early death defined as death within 14 days of hospital admission</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Sepsis</condition>
  <condition>Shock, Septic</condition>
  <arm_group>
    <arm_group_label>Sepsis cohort</arm_group_label>
    <description>Inclusion criteria&#xD;
Patients meeting the Sepsis-3 definition of sepsis or septic shock (the sequential organ failure assessment (SOFA) score will be used for organ failure assessment for Sepsis-3 criteria)&#xD;
Treatment with an institutional, evidence-based guideline management bundle for sepsis&#xD;
Within 24 hrs of sepsis recognition&#xD;
Exclusion criteria:&#xD;
alternative/confounding diagnosis causing shock (e.g., myocardial infarction or pulmonary embolus),&#xD;
uncontrollable source of sepsis (e.g., irreversible disease state such as unresectable dead bowel),&#xD;
advanced directives limiting resuscitative efforts,&#xD;
organ transplant recipient on immunosuppressive agents,&#xD;
known pregnancy,&#xD;
inability to obtain informed consent,&#xD;
HIV/AIDS with CD4 count &lt; 200,&#xD;
absolute neutrophil count &lt; 500</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood collection for serum, plasma, leukocytes samples for RNA extraction, and PBMC&#xD;
      collection for RNA sequence analysis. DNA samples may also be obtained.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients meeting the Sepsis-3 definition of sepsis and being treated with&#xD;
        institutional evidence-based care bundles.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patients meeting the Sepsis-3 definition of sepsis or septic shock&#xD;
&#xD;
          -  Treatment with an institutional, evidence-based guideline management bundle for sepsis&#xD;
             within 24 hrs of sepsis recognition&#xD;
&#xD;
          -  Sequential organ failure assessment (SOFA) score will be used for organ failure&#xD;
             assessment.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  a) alternative/confounding diagnosis causing shock (e.g., myocardial infarction or&#xD;
             pulmonary embolus)&#xD;
&#xD;
          -  b) uncontrollable source of sepsis (e.g., irreversible disease state such as&#xD;
             unresectable dead bowel)&#xD;
&#xD;
          -  c) advanced directives limiting resuscitative efforts&#xD;
&#xD;
          -  d) organ transplant recipient on immunosuppressive agents&#xD;
&#xD;
          -  e) known pregnancy&#xD;
&#xD;
          -  f) inability to obtain informed consent&#xD;
&#xD;
          -  g) HIV/AIDS with CD4 count &lt; 200, h) absolute neutrophil count &lt; 500. These criteria&#xD;
             are justified by numerous prior studies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faheem Guirgis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Morgan Henson, MPH</last_name>
    <phone>904-244-4986</phone>
    <email>Morgan.Henson@jax.ufl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Kennedy</last_name>
    <phone>904-244-4986</phone>
    <email>Amy.Kennedy@jax.ufl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2020</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

